Genistra Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 4.21%
- Profit Growth -11.44%
- Ebitda 39.26%
- Net Worth 41.07%
- Total Assets 0.34%
About Genistra Life Sciences
Genistra Life Sciences Private Limited (GLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 June 2012 and has a history of 12 years and eight months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Manian Jayabalan, Timma Saravanesh, Radhakrishnan Velrajan, and One other member serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74990TN2012PTC086385
- Company No.
086385
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jun 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Genistra Life Sciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manian Jayabalan  | Director | 19-Jun-2012 | Current |
| Timma Saravanesh | Director | 19-Jun-2012 | Current |
| Radhakrishnan Velrajan | Director | 19-Jun-2012 | Current |
| Chellaperumalpillai Muthiahpillay | Director | 19-Jun-2012 | Current |
Financial Performance of Genistra Life Sciences.
Genistra Life Sciences Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 4.21% increase. The company also saw a substantial fall in profitability, with a 11.44% decrease in profit. The company's net worth Soared by an impressive increase of 41.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genistra Life Sciences?
In 2018, Genistra Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genistra Life Sciences?
Unlock and access historical data on people associated with Genistra Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genistra Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genistra Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
